# Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

> **NCT04848064** · PHASE1 · RECRUITING · sponsor: **John Reneau** · enrollment: 12 (estimated)

## Conditions studied

- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Adult T-Cell Leukemia/Lymphoma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Mogamulizumab
- **BIOLOGICAL:** Natural Killer Cell Therapy
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04848064
- **Lead sponsor:** John Reneau
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-06
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04848064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04848064, "Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04848064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*